A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
- Status
- RECRUITING
- Phase
- N/A
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Status
- RECRUITING
- Phase
- PHASE3
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
- Status
- RECRUITING
- Phase
- NA
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
- Status
- RECRUITING
- Phase
- PHASE2
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Whole Body MRI in Oncology
- Status
- RECRUITING
- Phase
- N/A
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
- Status
- RECRUITING
- Phase
- NA
Pre-malignant States to Hematologic Malignancies in Firefighters
- Status
- RECRUITING
- Phase
- N/A
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2